Compare MRK & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRK | NVO |
|---|---|---|
| Founded | 2000 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.8B | 199.4B |
| IPO Year | 1997 | 2001 |
| Metric | MRK | NVO |
|---|---|---|
| Price | $147.94 | $40.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 28 | 14 |
| Target Price | ★ $161.53 | $45.74 |
| AVG Volume (30 Days) | 7.3M | ★ 8.6M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | 2.31% | ★ 3.12% |
| EPS Growth | ★ 8.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,011,000,000.00 | N/A |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $3.30 | $1.30 |
| P/E Ratio | ★ N/A | $13.60 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $91.49 | $35.12 |
| 52 Week High | $157.00 | $64.16 |
| Indicator | MRK | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 53.41 |
| Support Level | $145.75 | $37.61 |
| Resistance Level | $154.15 | $41.41 |
| Average True Range (ATR) | 3.99 | 0.78 |
| MACD | 0.15 | 0.25 |
| Stochastic Oscillator | 59.32 | 52.84 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.